Skip to main content
Top
Published in: Medical Oncology 12/2014

01-12-2014 | Original Paper

Prognosis in very young women with triple-negative breast cancer: retrospective study of 216 cases

Authors: Ying Liu, Tao Xin, Da-yong Huang, Wei-xi Shen, Li Li, Yan-ju Lv, Ying-hua Jin, Xiao-wei Song, Chong Teng, Qiu-ying Jiang

Published in: Medical Oncology | Issue 12/2014

Login to get access

Abstract

The aim of this investigation was to compare clinical pathological characteristics and prognosis of very young and older triple-negative breast cancer (TNBC) patients in order to assess their relevance to TNBC in an younger population. Data of TNBC patients diagnosed between 2002 and 2007 were retrospectively analyzed by computer based chart information. Baseline tumor characteristics, biological markers, and patients’ prognosis were compared between very young (≤35 years) and older (>35 years) TNBC patients. In the 216 cases of operable TNBC patients, 48 (22.2 %) were ≤35 years and 168 (77.8 %) were >35 years. Very young TNBC patients had showed a high clinical stage, more positive lymph nodes, Ck5/6 and/or EGFR expression (P = 0.049, 0.006, and 0.011, respectively). Compared to older TNBC patients, very young TNBC patients have short disease-free survival (P = 0.031), while no significant difference was found in overall survival (OS) (P = 0.075). In multivariate analysis, lymph node metastatic status was a significant predictor of OS. TNBC of very young patients is an aggressive breast cancer subtype, but the overall survival of both young and older TNBC patients did not have significant differences.
Literature
1.
go back to reference Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger post-menopasual patients. Cancer. 2004;101:1302–10.PubMedCrossRef Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger post-menopasual patients. Cancer. 2004;101:1302–10.PubMedCrossRef
2.
go back to reference Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273–9.PubMedCrossRef Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273–9.PubMedCrossRef
3.
go back to reference Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81.PubMedCrossRef Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81.PubMedCrossRef
4.
go back to reference Mise M, Higashide S, Hashimoto K, et al. Clinicopathological features of young patients with triple negative breast cancer. Gan To Kagaku Ryoho. 2009;36(10):1677–81. Mise M, Higashide S, Hashimoto K, et al. Clinicopathological features of young patients with triple negative breast cancer. Gan To Kagaku Ryoho. 2009;36(10):1677–81.
5.
go back to reference Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004;4:82. Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004;4:82.
6.
go back to reference Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol. 2010;28(12):2038–45.PubMedCentralPubMedCrossRef Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol. 2010;28(12):2038–45.PubMedCentralPubMedCrossRef
7.
go back to reference Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicareclaims data. J Clin Oncol. 2001;19(5):1455–61.PubMed Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicareclaims data. J Clin Oncol. 2001;19(5):1455–61.PubMed
8.
go back to reference Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 2010;21:1974–81.PubMedCrossRef Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 2010;21:1974–81.PubMedCrossRef
9.
go back to reference Ring A, Sestak I, Baum M, et al. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone orin combination trial. J Clin Oncol. 2011;1029(32):4266–72.CrossRef Ring A, Sestak I, Baum M, et al. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone orin combination trial. J Clin Oncol. 2011;1029(32):4266–72.CrossRef
10.
go back to reference Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer. 2005;41:1446–52.PubMedCrossRef Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer. 2005;41:1446–52.PubMedCrossRef
11.
go back to reference Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef
12.
go back to reference Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef
13.
go back to reference Foulkes WD, Smith IE, Reis-Filho JS. Triple negative breast cancer. N Engl J Med. 2010;363(20):1938–48.PubMedCrossRef Foulkes WD, Smith IE, Reis-Filho JS. Triple negative breast cancer. N Engl J Med. 2010;363(20):1938–48.PubMedCrossRef
14.
go back to reference Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.PubMedCrossRef Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.PubMedCrossRef
15.
go back to reference Yang MT, Rong TH, Huang ZF, et al. Clinical analysis of resectable breast cancer: a report of 6 263 cases. Ai Zheng. 2005;24:327–31.PubMed Yang MT, Rong TH, Huang ZF, et al. Clinical analysis of resectable breast cancer: a report of 6 263 cases. Ai Zheng. 2005;24:327–31.PubMed
16.
go back to reference Han W. Kang SY: relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119:193–200.PubMedCrossRef Han W. Kang SY: relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119:193–200.PubMedCrossRef
17.
go back to reference Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.PubMedCentralPubMedCrossRef Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.PubMedCentralPubMedCrossRef
18.
19.
go back to reference Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97–103.PubMedCrossRef Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97–103.PubMedCrossRef
20.
go back to reference Winchester DP, Osteen RT, Menck HR. The national cancer data base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 1996;78:1838–43.PubMedCrossRef Winchester DP, Osteen RT, Menck HR. The national cancer data base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 1996;78:1838–43.PubMedCrossRef
21.
go back to reference Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2010;17:118–24.PubMedCrossRef Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2010;17:118–24.PubMedCrossRef
22.
go back to reference Rodríguez-Pinilla SM, Sarrió D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node negative invasive breast carcinomas. Clin Cancer Res. 2006;12(5):1533–9.PubMedCrossRef Rodríguez-Pinilla SM, Sarrió D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node negative invasive breast carcinomas. Clin Cancer Res. 2006;12(5):1533–9.PubMedCrossRef
23.
go back to reference Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef
24.
go back to reference Konigsberg R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (P65) patients. Eur J Cancer. 2012. Konigsberg R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (P65) patients. Eur J Cancer. 2012.
Metadata
Title
Prognosis in very young women with triple-negative breast cancer: retrospective study of 216 cases
Authors
Ying Liu
Tao Xin
Da-yong Huang
Wei-xi Shen
Li Li
Yan-ju Lv
Ying-hua Jin
Xiao-wei Song
Chong Teng
Qiu-ying Jiang
Publication date
01-12-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0222-2

Other articles of this Issue 12/2014

Medical Oncology 12/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.